Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

被引：0

作者：

Marta Milà-Alomà

Nicholas J. Ashton

Mahnaz Shekari

Gemma Salvadó

Paula Ortiz-Romero

Laia Montoliu-Gaya

Andrea L. Benedet

Thomas K. Karikari

Juan Lantero-Rodriguez

Eugeen Vanmechelen

Theresa A. Day

Armand González-Escalante

Gonzalo Sánchez-Benavides

Carolina Minguillon

Karine Fauria

José Luis Molinuevo

Jeffrey L. Dage

Henrik Zetterberg

Juan Domingo Gispert

Marc Suárez-Calvet

Kaj Blennow

机构：

[1] Pasqual Maragall Foundation,Barcelonaβeta Brain Research Center (BBRC)

[2] IMIM (Hospital del Mar Medical Research Institute),Department of Psychiatry and Neurochemistry

[3] Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable,Wallenberg Centre for Molecular and Translational Medicine

[4] Instituto de Salud Carlos III,Translational Neuroimaging Laboratory

[5] Universitat Pompeu Fabra,Department of Psychiatry

[6] Institute of Neuroscience and Physiology,Lilly Research Laboratories

[7] University of Gothenburg,Stark Neurosciences Research Institute

[8] University of Gothenburg,Clinical Neurochemistry Laboratory

[9] King’s College London,Department of Neurodegenerative Disease

[10] Institute of Psychiatry,Servei de Neurologia

[11] Psychology & Neuroscience,undefined

[12] Maurice Wohl Clinical Neuroscience Institute,undefined

[13] NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation,undefined

[14] McGill Centre for Studies in Aging,undefined

[15] McGill University,undefined

[16] University of Pittsburgh,undefined

[17] ADx NeuroSciences NV,undefined

[18] Eli Lilly and Company,undefined

[19] Indiana University School of Medicine,undefined

[20] Sahlgrenska University Hospital,undefined

[21] UCL Institute of Neurology,undefined

[22] UK Dementia Research Institute at UCL,undefined

[23] Centro de Investigación Biomédica en Red Bioingeniería,undefined

[24] Biomateriales y Nanomedicina,undefined

[25] Hospital del Mar,undefined

来源：

Nature Medicine | 2022年 / 28卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s disease are needed to facilitate the initial screening process of participants in disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient Aβ pathology, but a comprehensive comparison with other putative blood biomarkers is lacking. In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40) were significantly changed in preclinical Alzheimer’s disease. However, plasma p-tau231 reached abnormal levels with the lowest Aβ burden. Plasma p-tau231 and p-tau217 had the strongest association with Aβ positron emission tomography (PET) retention in early accumulating regions and associated with longitudinal increases in Aβ PET uptake in individuals without overt Aβ pathology at baseline. In summary, plasma p-tau231 and p-tau217 better capture the earliest cerebral Aβ changes, before overt Aβ plaque pathology is present, and are promising blood biomarkers to enrich a preclinical population for Alzheimer’s disease clinical trials.

引用

页码：1797 / 1801

页数：4

共 41 条

[1]

Palmqvist S(2020)Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders JAMA 324 772-724

[2]

Ashton NJ(2021)Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology Acta Neuropathol. 141 709-433

[3]

Karikari TK(2020)Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts Lancet Neurol. 19 422-278

[4]

Lantero Rodriguez J(2020)Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline Acta Neuropathol. 140 267-562

[5]

Jack CR(2018)NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease Alzheimers Dement. 14 535-997

[6]

Mielke MM(2018)Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography Alzheimers Dement. 14 989-3516

[7]

Pereira JB(2021)Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease Brain 144 3505-386

[8]

Janelidze S(2020)Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia Nat. Med. 26 379-1154

[9]

Suárez-Calvet M(2020)Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected EMBO Mol. Med. 12 e12921-1371

[10]

Chatterjee P(2022)Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer’s disease Alzheimers Dement. 18 1141-92

← 1 2 3 4 5 →